Related Experiment Video
Updated: Jul 15, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
Yuki Yuza1, Karen A Glatt, Jingrui Jiang
1Department of Medical Oncology, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract:
Targeted cancer therapies impede cancer cell growth by inhibiting the function of activated oncogene products. Patients with non-small cell lung cancer and somatic mutations of EGFR can have a dramatic response to treatment with erlotinib and gefitinib; different somatic mutations are associated with different times to progression and survival. In this study, the relative and absolute potencies of two distinct EGFR tyrosine kinase inhibitors, erlotinib and an investigational irreversible inhibitor, HKI-272, were found to vary significantly in a panel of Ba/F3 cells transformed by representative EGFR somatic mutations. HKI-272 more potently inhibited the primary exon 20 insertion mutants, the secondary erlotinib-resistance mutants including T790M and many erlotinib-sensitive mutants including L858R. In contrast, erlotinib is a more potent inhibitor of the major exon 19 deletion mutants than is HKI-272. Analyses of EGFR autophosphorylation patterns confirmed the mutation-specific variation in relative potency of these tyrosine kinase inhibitors. Our finding that distinct EGFR inhibitors are more effective in vitro for different mutant forms of the protein suggests that tyrosine kinase inhibitor treatment could be tailored to specific EGFR mutations. More broadly, these results imply that the development and deployment of targeted therapies should focus on inhibition of specific cancer-causing mutations, not only on the mutated target.
Insights
Different EGFR inhibitors show varying effectiveness against specific non-small cell lung cancer mutations. Tailoring tyrosine kinase inhibitor treatment to individual EGFR mutations may improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted cancer therapies, including EGFR tyrosine kinase inhibitors (TKIs), are crucial for treating non-small cell lung cancer (NSCLC) with specific EGFR mutations.
- Erlotinib and gefitinib are established EGFR TKIs, but their efficacy varies based on distinct somatic mutations, impacting patient survival and progression.
- Understanding the differential potency of various EGFR inhibitors against specific mutations is key to optimizing treatment strategies.
Purpose of the Study:
- To compare the relative and absolute potencies of erlotinib and HKI-272, an investigational irreversible inhibitor, against a panel of EGFR somatic mutations.
- To investigate the mutation-specific efficacy of distinct EGFR tyrosine kinase inhibitors in vitro.
- To explore the potential for tailoring TKI treatment based on specific EGFR mutation profiles.
Main Methods:
- Utilized Ba/F3 cell lines engineered with representative EGFR somatic mutations.
- Assessed the inhibitory potency of erlotinib and HKI-272 against these mutated EGFR variants.
- Analyzed EGFR autophosphorylation patterns to confirm inhibitor efficacy and specificity.
Main Results:
- HKI-272 demonstrated greater potency against primary exon 20 insertion mutants, T790M resistance mutants, and several erlotinib-sensitive mutants (e.g., L858R).
- Erlotinib exhibited higher potency against major exon 19 deletion mutants compared to HKI-272.
- EGFR autophosphorylation analyses confirmed significant, mutation-specific variations in the relative potencies of these TKIs.
Conclusions:
- Distinct EGFR inhibitors exhibit differential efficacy against specific EGFR mutations in vitro.
- The findings support the potential for personalized TKI therapy tailored to individual EGFR mutation profiles in NSCLC.
- Future targeted therapy development should prioritize inhibiting specific cancer-driving mutations rather than the general mutated target.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
01:22Dose-Response Relationship: Potency and Efficacy
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase